For example, a clinic trail showed that WT1 peptide vaccination in WT1-expressing AML and MDS patients without curative treatment option had clinical benefit including complete remission or stable diseases (SDs) with more than 50% blast reduction. The gene discussed is WT1; the disease is myelodysplastic syndrome.